NeOnc Technologies Secures UAE IND Approval for NEO212 Following Successful Phase 1 Completion, Advancing Toward Global Phase 2 Development
NeOnc Technologies secured Investigational New Drug (IND) approval from the UAE Department of Health for NEO212, an oral conjugate drug targeting aggressive brain tumors, following successful Phase 1 dose escalation. The clearance supports advancing NEO212 into Phase 2 trials in the UAE, complementing ongoing discussions with the U.S. FDA for poten…